Subcutaneous · GLP-1 / GLP-2 dual
Dapiglutide
5 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
5
Active
1
Recruiting
0
Completed
3
Sites
2
Countries
2
Endpoints
115
Composite endpoints
3
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
11
8
7
5
5
4
4
4
3
3
2
2
2
1
1
1
1
1
1
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
5 of 5
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06000891A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Dapiglutide, GLP-1 / incretin class catch-all Obesity / overweight | BMI 27-39.9 | Ph 1 | Terminated | 1 | Feb 2025 | — | |
| DREAMDapiglutide for the Treatment of Obesity | Dapiglutide Obesity / overweight | BMI ≥30 | Ph 2 | Active, not recruiting | 1 | Apr 2024 | 1 | |
| NCT03994549A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Dapiglutide, GLP-1 / incretin class catch-all Healthy volunteers | BMI 18.5-28 | Early Ph 1 | Completed | 1 | Nov 2020 | — | |
| NCT06758583A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide | Dapiglutide Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 1 | Apr 2025 | — | |
| NCT04612517A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Dapiglutide Healthy volunteers | BMI 18.5-28 | Early Ph 1 | Completed | 1 | Aug 2021 | — |